ATE397014T1 - Hiv-peptide, antigene und impfstoffzusammensetzungen - Google Patents

Hiv-peptide, antigene und impfstoffzusammensetzungen

Info

Publication number
ATE397014T1
ATE397014T1 AT00911492T AT00911492T ATE397014T1 AT E397014 T1 ATE397014 T1 AT E397014T1 AT 00911492 T AT00911492 T AT 00911492T AT 00911492 T AT00911492 T AT 00911492T AT E397014 T1 ATE397014 T1 AT E397014T1
Authority
AT
Austria
Prior art keywords
hiv
antigens
peptides
vaccine compositions
hiv peptides
Prior art date
Application number
AT00911492T
Other languages
English (en)
Inventor
Birger Soerensen
Original Assignee
Bionor Immuno As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionor Immuno As filed Critical Bionor Immuno As
Application granted granted Critical
Publication of ATE397014T1 publication Critical patent/ATE397014T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
AT00911492T 1999-03-04 2000-03-02 Hiv-peptide, antigene und impfstoffzusammensetzungen ATE397014T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO19991078A NO311807B1 (no) 1999-03-04 1999-03-04 HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV

Publications (1)

Publication Number Publication Date
ATE397014T1 true ATE397014T1 (de) 2008-06-15

Family

ID=19903050

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00911492T ATE397014T1 (de) 1999-03-04 2000-03-02 Hiv-peptide, antigene und impfstoffzusammensetzungen

Country Status (23)

Country Link
US (4) US6706859B1 (de)
EP (1) EP1159298B1 (de)
JP (5) JP2002541069A (de)
CN (4) CN101328209A (de)
AT (1) ATE397014T1 (de)
AU (1) AU771827B2 (de)
BR (1) BR0008741A (de)
CA (1) CA2363947C (de)
CY (1) CY1108299T1 (de)
CZ (1) CZ300505B6 (de)
DE (1) DE60039036D1 (de)
DK (1) DK1159298T3 (de)
EA (1) EA004802B9 (de)
ES (1) ES2307496T4 (de)
HK (1) HK1044778B (de)
HU (1) HU229282B1 (de)
ID (1) ID30497A (de)
NO (1) NO311807B1 (de)
NZ (4) NZ525752A (de)
PT (1) PT1159298E (de)
SK (1) SK287382B6 (de)
WO (1) WO2000052040A1 (de)
ZA (1) ZA200107072B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1635876A (zh) 2000-02-04 2005-07-06 杜克大学 人免疫缺陷病毒疫苗
NO314588B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
SG170092A1 (en) 2006-03-10 2011-04-29 Peptcell Ltd Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
JP5775451B2 (ja) 2008-06-19 2015-09-09 バリエーション バイオテクノロジーズ インコーポレイティド インフルエンザを処置するための組成物および方法
MX2012000372A (es) 2009-07-06 2012-02-28 Variation Biotechnologies Inc Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
JP6069212B2 (ja) * 2010-12-02 2017-02-01 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ ペプチド骨格設計
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP4008354A1 (de) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Verfahren und zusammensetzungen für therapeutika
US20150174235A1 (en) 2012-06-06 2015-06-25 Bionor Immuno As Vaccine
WO2013182661A1 (en) * 2012-06-06 2013-12-12 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
EP3033106A1 (de) * 2013-08-14 2016-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Immunadjuvanzienzusammensetzungen und verwendungen davon
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
WO2015086738A2 (en) * 2013-12-11 2015-06-18 Bionor Immuno As Hiv vaccine
EP3099322A1 (de) 2014-01-27 2016-12-07 Bionor Immuno AS Verfahren zur impfung gegen hiv
WO2015110659A1 (en) * 2014-01-27 2015-07-30 Bionor Immuno As Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response
CA2936335A1 (en) 2014-01-27 2015-07-30 Bionor Immuno As Dosage regimen for hiv vaccine
WO2015154031A1 (en) 2014-04-03 2015-10-08 Amgen Inc. Method for preparing amg 416
EP3166633A1 (de) 2014-07-11 2017-05-17 Bionor Immuno AS Verfahren zur reduktion und/oder verzögerung der pathologischen wirkungen des menschlichen immunschwächevirus i (hiv) oder zur verringerung des risikos der entwicklung von erworbenem immundefizienzsyndrom (aids)
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US20180140694A1 (en) 2015-05-04 2018-05-24 Bionor Immuno As Dosage regimen for hiv vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62164696A (ja) 1986-01-06 1987-07-21 エフ．ホフマン　―　ラ　ロシュ　アーゲー ＨＴＬＶ−３ｇａｇ遺伝子の発現
US4925784A (en) 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
GB8629116D0 (en) 1986-12-05 1987-01-14 Hoffmann La Roche Env/gag polypeptides
IE63455B1 (en) 1987-09-04 1995-04-19 Int Murex Tech Corp Immunoassay and biological constructs for use therein
US4888290A (en) * 1987-11-06 1989-12-19 Coulter Corporation Monoclonal antibody specific to HIV antigens
EP0356007A3 (de) 1988-07-22 1991-07-03 Medical Research Council Antigenische Determinanten
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
SE468168B (sv) 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
FR2703252B1 (fr) * 1993-03-31 1996-09-06 Fernand Narbey Torossian Complexe immunomodulateur anti SIDA.
AU7101294A (en) * 1993-06-07 1995-01-03 Endocon, Inc. Implant stimulated cellular immunity
EP0728764A4 (de) * 1993-10-19 1999-01-20 Ajinomoto Kk Peptide das eine immunantwort gegen hiv unduziert und arzneimittel die esenthaelt zur vorbeugung oder behandlung von aids
FR2731013B1 (fr) * 1995-02-27 1997-05-16 Inst Nat Sante Rech Med Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
WO1998040744A1 (de) * 1997-03-10 1998-09-17 Roche Diagnostics Gmbh Verfahren zur simultanen bestimmung von hiv-antigenen und hiv-antikörpern

Also Published As

Publication number Publication date
CN1346367A (zh) 2002-04-24
NO991078D0 (no) 1999-03-04
DK1159298T3 (da) 2008-08-25
SK287382B6 (sk) 2010-08-09
CY1108299T1 (el) 2014-02-12
US7709004B2 (en) 2010-05-04
DE60039036D1 (de) 2008-07-10
NZ525751A (en) 2004-10-29
JP2013032386A (ja) 2013-02-14
ES2307496T4 (es) 2015-03-06
US7311915B2 (en) 2007-12-25
EP1159298B1 (de) 2008-05-28
ID30497A (id) 2001-12-13
NO311807B1 (no) 2002-01-28
AU3335800A (en) 2000-09-21
JP5695012B2 (ja) 2015-04-01
ES2307496T3 (es) 2008-12-01
CN101328210A (zh) 2008-12-24
CN101328208A (zh) 2008-12-24
HK1044778B (zh) 2009-04-24
ZA200107072B (en) 2002-11-27
US20040259797A1 (en) 2004-12-23
CA2363947C (en) 2008-05-20
NZ525752A (en) 2004-10-29
JP2013032384A (ja) 2013-02-14
NZ525753A (en) 2004-10-29
PT1159298E (pt) 2008-09-04
BR0008741A (pt) 2002-01-08
US6706859B1 (en) 2004-03-16
CA2363947A1 (en) 2000-09-08
CN101328209A (zh) 2008-12-24
HU229282B1 (en) 2013-10-28
JP5814331B2 (ja) 2015-11-17
US20080107670A1 (en) 2008-05-08
JP2014043468A (ja) 2014-03-13
JP5313998B2 (ja) 2013-10-09
CZ20013195A3 (cs) 2002-02-13
EA004802B1 (ru) 2004-08-26
JP2002541069A (ja) 2002-12-03
US7709003B2 (en) 2010-05-04
CN100387617C (zh) 2008-05-14
HK1044778A1 (en) 2002-11-01
JP2011074081A (ja) 2011-04-14
SK12402001A3 (sk) 2002-02-05
US20080107669A1 (en) 2008-05-08
HUP0200265A2 (en) 2002-06-29
EA004802B9 (ru) 2015-03-31
CZ300505B6 (cs) 2009-06-03
EP1159298A1 (de) 2001-12-05
AU771827B2 (en) 2004-04-01
WO2000052040A1 (en) 2000-09-08
NZ514619A (en) 2003-10-31
EA200100943A1 (ru) 2002-02-28
NO991078L (no) 2000-09-05
JP5695010B2 (ja) 2015-04-01

Similar Documents

Publication Publication Date Title
DE60039036D1 (de) Hiv-peptide, antigene und impfstoffzusammensetzungen
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
BR0210598A (pt) Complexo solúvel que compreende uma glicoproteìna retroviral de superfìcie
Gilljam Envelope glycoproteins of HIV-1, HIV-2, and SIV purified with Galanthus nivalis agglutinin induce strong immune responses
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
DE60037450D1 (de) Funf-helix protein
DE68927348D1 (de) Künstlicher impfstoff gegen aids-virus
ATE154610T1 (de) Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung
WO2002020555A3 (en) Hiv peptides from tat, rev and wef conserved regions and their application as e.g.vaccine components
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
Kennedy et al. Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelope.
DE60044259D1 (de) HUMANE ANTI-CHEMOKINREZEPTOREN IgM ANTIKÖRPER
Lizeng et al. Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection
DeVICO et al. Purification and partial characterization of human immunodeficiency virus type 2 reverse transcriptase
Pyle et al. Purification and characterization of the external envelope glycoprotein from two human immunodeficiency virus type 1 variants, HTLV-IIIB and HTLV-IIIRF
AU4832097A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
Wieland et al. Antigenic domains of the HIV-1 vif protein as recognized by human sera and murine monoclonal antibodies
Chen et al. A common immunological epitope existing between HIV-1 gp41 and human interferon-α and-β
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
RU2000106709A (ru) Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5
FR2874017B1 (fr) Peptides vih-1 modifies et leur utilisation en detection d'anticorps anti-vih
ATE122236T1 (de) Vorläufer des hüllenglykoproteins des hiv-2 retrovirus und verwandte antigene.
Gnann Jr et al. Designing Peptides to Immunologically Distinguish Specific Human Immunodeficiency Virus Isolates
BR9711809A (pt) Polipeptìdeo antigênico ou imunogênico, processos para tratar ou prevenir uma doença ou distúrbio em um indivìduo provocado por infecção com htlv-i, e com htlv-ii, para elicitar em um indivìduo a produção de anticorpos que especificamente ligam-se às proteìnas envelopes htlv-ii e htlv-i, e, para gerar uma resposta imune em um indivìduo

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1159298

Country of ref document: EP